drugset / Trial / NCT00668096

A Randomised Study of Levitra to Treat Men With Erections Problems and Previously Untreated With Similar Therapy.

NCT00668096

Phase 4 Completed 260 enrolled Bayer
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of this study was to evaluate the efficacy and tolerability of the phosphodiesterase type 5 inhibitor (PDE5 inhibitor), vardenafil, in a broad population of subjects with erectile dysfunction of different aetiologies and severity, who have not been previously treated with a PDE5 inhibitor; Efficacy and safety was compared with placebo.

Timeline

Start
2004-05
Primary completion
2005-01
Completion
2005-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Vardenafil Small molecule 5 mg Oral
Subject Vardenafil Small molecule 10 mg Oral
Subject Vardenafil Small molecule 20 mg Oral

Indications